Lineage Cell Therapeutics Inc - Company Profile

Powered by

All the data and insights you need on Lineage Cell Therapeutics Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Lineage Cell Therapeutics Inc Strategy Report

  • Understand Lineage Cell Therapeutics Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Lineage Cell Therapeutics Inc: Overview

Select Item

Lineage Cell Therapeutics Inc (Lineage) formerly known as BioTime Inc, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. Lineage’s lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration, Opc1 in acute spinal cord injury, and Vac2 for non-small cell lung cancer. The company has subsidiaries in Israel, Singapore, and the US. Lineage is headquartered in Carlsbad, California, the US.

 Gain a 360-degree view of Lineage Cell Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Lineage Cell Therapeutics Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 2173 Salk Ave Ste 200, Carlsbad, California, 92008-7354
Website lineagecell.com
Telephone 1 510 5213390
No of Employees 75
Industry Medical Equipment
Ticker Symbol & Exchange LCTX (AFM)
Revenue (2022) $8.9M -39.2% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 18.2% (2022 vs 2021)
Market Cap* $245.1M
Net Profit Margin (2022) XYZ -34.4% (2022 vs 2021)
* As of and is in US$
View Lineage Cell Therapeutics Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Lineage Cell Therapeutics Inc premium industry data and analytics

11+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

9

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Lineage Cell Therapeutics Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Cell/Drug Delivery
Renevia:
Facial Lipoatrophy
XYZ
XYZ
XYZ
Understand Lineage Cell Therapeutics Inc portfolio and identify potential areas for collaboration Understand Lineage Cell Therapeutics Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In February, the company entered into an option and license agreement with Eterna Therapeutics Inc for the development of novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell lines.
2022 New Products/Services In November, the company's partner Genentech launched a Phase 2a, multicenter, open-label, single arm clinical study of RG6501 (OpRegen).
2021 Contracts/Agreements In June, the company entered into an option agreement with Amasa Therapeutics for supply and use of Clinical-Grade Hystem
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Lineage Cell Therapeutics Inc Baxter International Inc Astellas Pharma Inc Athersys Inc Kineta Inc
Headquarters United States of America United States of America Japan United States of America United States of America
City Carlsbad Deerfield Chuo-Ku Cleveland Mercer Island
State/Province California Illinois Tokyo Ohio Washington
No. of Employees 75 60,000 14,484 24 11
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Brian M. Culley Chief Executive Officer Executive Board 2018 51
Jill Howe Chief Financial Officer Senior Management 2022 -
Alfred D. Kingsley Chairman Non Executive Board 2009 77
Derek Kelaita Vice President - Business Development Senior Management 2019 -
Gary S. Hogge Senior Vice President - Clinical and Medical Affairs Senior Management 2018 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Lineage Cell Therapeutics Inc key executives to enhance your sales strategy Gain insight into Lineage Cell Therapeutics Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward